Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Manufacturers	Review Status	Status Date	View
JYSZ2200037	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	License Renew	2022-08-01					view
JYSB2400237	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2024-11-01					view
JYSB2400074	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2024-04-04					view
JYSB2400057	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2024-03-12					view
JYSB2400009	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2024-01-18					view
JYSB2300201	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2023-12-01					view
JYSB2300193	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2023-11-08					view
JYSB2300150	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2023-09-01					view
JYSB2300100	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2023-05-25					view
JYSB2200007	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2022-01-13					view
JYSB2101134	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-09-13					view
JYSB2101131	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-09-14					view
JYSB2101099	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-08-10					view
JYSB2101098	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-08-05					view
JYSB2101097	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products(3.1)	Supplementary Application	2021-08-03					view
JYSB2101022	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-05-07					view
JYSB2101012	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-04-23					view
JYSB2100036	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2021-01-28	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2021-01-27	view
JYSB2000618	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2020-12-14	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2021-03-12	view
JYSB2000337	帕博利珠单抗注射液	Pembrolizumab	Injection	Biological Products	Supplementary Application	2020-07-04	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	In Review	2020-07-03	view